Chitosan Brushes vs Air-Abrasive Devices on Peri-implant Mucositis Treatment: A Randomized Clinical
NCT ID: NCT06287957
Last Updated: 2024-03-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
54 participants
INTERVENTIONAL
2024-03-01
2025-02-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Hydrogel Application in the Treatment of Periodontitis and Peri-implantitis
NCT06740123
A Chitosan Brush and Enamel Matrix Derivative for Non-surgical Treatment of Furcations
NCT06684769
Chitosan Nano-hydroxyapatite Hydrogel in Non-Surgical Treatment of Intrabony Defect
NCT06373757
Non-surgical Step 3 Periodontal Treatment With/Without Adjunctive Protocol - Pilot RCT.
NCT06438354
Effect of Hyaluronic Acid in the Treatment of Periodontal Pockets
NCT02170857
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Experimental procedures and follow-ups Bleeding on probing (0,1,2,3), plaque index (+,-) and pocket probing depth will be recorded for each visit. Before the procedure, the patient will be randomly assigned to one of four groups and records will be kept. In the frst visit of the patient, necessary actions will be taken according to the group to which the patient is assigned. The implant periphery of the patients assigned to the chitosan brush group will be debrided with a chitosan brush with circular movements. The implants of the patients assigned to the air abrasive device group will be cleaned in the same way with circular movements. The debrided area of both groups will be washed with sterile serum after the treatment. Patients will be called at the 2nd, 4th and 12th weeks and compared with the records kept.
The number of cases to be taken in total, 12 cases, was determined as 48. There will be 54-55 cases with 10% drop out share.
GPOWER PROTOCOL F tests - ANOVA: Repeated measures, between factors Analysis: A priori: Compute required sample size Input: Effect size f = 0.4982302 α err prob = 0.05 Power (1-β err prob) = 0.95 Number of groups = 4 Number of measurements = 4 Corr among rep measures = 0.5 Output: Noncentrality parameter λ = 19.0643199 Critical F = 2.8164658 Numerator df = 3.0000000 Denominator df = 44.0000000 Total sample size = 48 Actual power = 0.9529658 For the results; Data will be analyzed with IBM SPSS V23. Repeated measures analysis of variance will be used to analyze quantitative data. For multiple comparisons, the Bonferroni test will be used. Analysis results will be presented as mean and standard deviation for quantitative data, and frequency and percentage for categorical data. The signifcance level will be taken as p\<0.05.
Peri-implant mucositis is the last reversible stage before peri-implantitis. Treatment of the disease at this stage is very important. When treated, bone loss around the implant will be prevented and implant survival will be prolonged.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ML
Patients with mini platform implants to be treated with Labrida Bioclean
Labrida BioClean
Debriding the tissue around the implant with Labrida Bioclean
RL
Patients with regular platform implants to be treated with Labrida Bioclean
Labrida BioClean
Debriding the tissue around the implant with Labrida Bioclean
ME
Patients with mini platform implants to be treated with Air-Flow Devices (EMS Handy 3.0 Perio Premium)
EMS Handy 3.0 Perio Premium
Debriding the tissue around the implant with Air-Flow Device
RE
Patients with regular platform implants to be treated with Air-Flow Devices (EMS Handy 3.0 Perio Premium)
EMS Handy 3.0 Perio Premium
Debriding the tissue around the implant with Air-Flow Device
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Labrida BioClean
Debriding the tissue around the implant with Labrida Bioclean
EMS Handy 3.0 Perio Premium
Debriding the tissue around the implant with Air-Flow Device
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Being over 18 years old,
* Being psychologically suitable,
* The teeth adjacent to the relevant implant are natural teeth,
* Having at least 1 implant in the maxillary or mandibular posterior region (teeth 4, 5, 6 and 7) and a cemented prosthesis that is not connected to other implants or teeth as its superstructure,
* Probing depth longer than 3 mm and shorter than 5 mm,
* Evidence of bleeding is required on probing.
Exclusion Criteria
* History of chemotherapy and/or radiotherapy received in the past or currently being received,
* Bone loss around the implant,
* Presence of an implant in the area adjacent to the relevant implant,
* Dentures combined with other implants or teeth,
* Screw-retained prostheses
* Uncontrolled diabetes
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Istanbul University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alper Gultekin
Dr.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Istanbul University
Istanbul, Fatih, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IU-DHF-AG-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.